IDSA GUIDELINES Bundle (free trial)

Leishmaniasis

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/774306

Contents of this Issue

Navigation

Page 30 of 39

31 8. See Recs. 61–66 regarding secondary prophylaxis in patients with HIV/AIDS-associated VL. Chronic maintenance therapy (secondary prophylaxis) should be given until the CD4 T-lymphocyte cell count consistently remains >200–350/mm 3 (see Recs. 61–66). 9. See Recs. 51–54 for additional perspective about treatment alternatives. Parenteral paromomycin appeared promising in clinical trials in India, but it is not available in North America. 10. Miltefosine has been effective in treating VL in India and adjacent areas of South Asia where resistance to pentavalent antimonials is prevalent. There is some evidence to support the use of miltefosine for VL acquired in East Africa. There is less available evidence to support its use in southern Europe and Latin America. 11. Resistance to pentavalent antimonials is well documented in India and has been reported from other areas. In general, pentavalent antimonial therapy should not be used for persons who acquired VL in India. 12. Personal communication Pierre Buffet, on the basis of expert opinion. 13. Contact information for use in military beneficiaries: a. Force Health Protection Division's 24-hour cell phone: 301-401-2768 b. Force Health Protection Division's email: usarmy.detrick.medcom- usammda.mbx.force-health-protection@mail.mil Footnotes for Tables 3a, 3b & 3c (cont'd)

Articles in this issue

Links on this page

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Leishmaniasis